Markets:

Overview

News

Currencies

International

Treasuries

Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

2.137 +0.077 (+3.72%)

Streaming Delayed Price Updated: 1:51 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alzamend Neuro, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 30, 2023

Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.

Via Benzinga

Crude Oil Falls Over 3%; Miromatrix Medical Shares Spike Higher ↗

October 30, 2023

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up 1.14% to 32,788.73 while the NASDAQ rose 0.98% to 12,766.33. The...

Via Benzinga

Topics Stocks

Why Alzamend Neuro (ALZN) Stock Is Nosediving Today ↗

October 30, 2023

Alzamend Neuro Inc (NASDAQ: ALZN) shares are trading lower by 31.2% to $0.12 Monday morning after the company announced a reverse stock split. What Happened?

Via Benzinga

Why Ault Alliance Are Rocketing Today ↗

July 12, 2023

Ault Alliance Inc (AMEX: AULT) shares are trading exponentially higher by over 147% after the company stated that

Via Benzinga

Nasdaq Gains Over 1%; McDonald's Reports Upbeat Earnings ↗

October 30, 2023

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 250 points on Monday. Following the market opening Monday, the Dow traded up 0.85% to 32,695.89 while the NASDAQ rose...

Via Benzinga

Topics Stocks

Alzamend Neuro Announces Reverse Stock Split

October 30, 2023

From Alzamend Neuro, Inc.

Via Business Wire

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001

October 23, 2023

From Alzamend Neuro, Inc.

Via Business Wire

EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder ↗

October 23, 2023

Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-MDD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for...

Via Benzinga

Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

October 02, 2023

From Alzamend Neuro, Inc.

Via Business Wire

EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder ↗

October 02, 2023

Alzamend Neuro Inc (NASDAQ: ALZN) received the FDA's "Study May Proceed" letter to initiate study AL001-BD01, a Phase 2A clinical study of AL001 for bipolar disorder type 1. The company expects the...

Via Benzinga

NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying ↗

September 27, 2023

The Dow Jones closed lower by around 388 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

September 22, 2023

From Alzamend Neuro

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 20, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 08, 2023

Via Benzinga

Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

August 30, 2023

From Alzamend Neuro

Via Business Wire

EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder ↗

August 30, 2023

Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-BD01, a Phase 2A study of AL001 for bipolar disorder.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 15, 2023

Via Benzinga

FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline ↗

July 07, 2023

The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.

Via Benzinga

EXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study ↗

June 22, 2023

Alzamend Neuro Inc (NASDAQ: ALZN) has identified a maximum tolerated dose (MTD) for developing AL001 from a multiple-ascending dose study as assessed by an independent safety review committee.

Via Benzinga

Why Yext Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗

June 07, 2023

Gainers

Via Benzinga

Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001

June 22, 2023

From Alzamend Neuro

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

June 07, 2023

We're starting the day off right with a breakdown of the biggest pre-market stock movers worth reading about on Wednesday!

Via InvestorPlace

Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference

June 13, 2023

From Alzamend Neuro

Via Business Wire

3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024 ↗

May 24, 2023

These biotech stocks with high return potential are poised to provide quick returns for investors who invest over the next year.

Via InvestorPlace

3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year ↗

May 11, 2023

These 3 penny stocks have 10X potential over the next twelve months, providing the right risk/reward bet for certain investors.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023 ↗

April 12, 2023

Via Benzinga

EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine ↗

April 03, 2023

Alzamend Neuro Inc (NASDAQ: ALZN) has initiated a Phase 1/2A trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of Alzheimer’s type.

Via Benzinga

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

April 04, 2023

From Ault Alliance, Inc.

Via Business Wire

KILL Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

April 03, 2023

Via Business Wire

Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

April 03, 2023

From Alzamend Neuro, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.